The Paris-based pharmaceutical company submitted an application to the FDA for Opill, a medication that’s been authorized since 1973, according to a July 11 press release.
A 2016 study found that nearly 3 out of 10 women had difficulty receiving a birth control prescription or refill — a statistic that HRA Pharma said could be lowered if Opill axes its prescription label.
“Moving a safe and effective prescription birth control pill to OTC will help more women and people access contraception without facing unnecessary barriers,” HRA Pharma’s chief strategic operations and innovation officer, Frédérique Welgryn, said.
The move comes after the U.S. Supreme Court overturned Roe v. Wade June 24, which has strained access to medication abortion pills, cancer drugs and emergency contraceptives such as Plan B.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
